CPC G01N 33/5743 (2013.01) [G01N 33/564 (2013.01)] | 9 Claims |
1. A method of treating a subject with melanoma, wherein the melanoma is Stage 0, Stage I or Stage II melanoma, the method comprising the steps of:
a. measuring the expression levels of a group of autoantibodies including anti-ZBTB7B, anti-PRKCH, anti-TP53, anti-PCTK1, anti-PQBP1, anti-UBE2V1, anti-IRF4, anti-MAPK8_tv2, anti-MSN and anti-TPM1 in a biological sample obtained from a subject;
b. comparing the levels of expressions of all of the autoantibodies in the group in the biological sample to reference values, wherein the reference values are representative of known or predetermined levels of the same autoantibodies in a reference sample or a plurality of reference samples from a subject or subjects that have never been diagnosed with cancer, melanoma or an autoimmune disease, wherein the expression levels of all of the autoantibodies in the group in the biological sample greater than the reference value provides an indication that the subject has melanoma;
c. identifying a subject that has melanoma from step (b); and
d. treating the subject identified in step (c) as having melanoma with a therapeutic regimen for preventing or delaying the progression of the melanoma, wherein the therapeutic regimen is selected from the group consisting of surgery, administration of a chemotherapeutic agent, radiotherapy, immunotherapy and targeted molecular therapy.
|